Q&A: Kristóf Ferenczi, firm managing partner, discusses the future of Kinstellar

Posted on |
Q&A: Kristóf Ferenczi, firm managing partner, discusses the future of Kinstellar

Can you share your journey in the legal field leading up to your current role as managing partner?

I started my legal career more than two decades ago as a trainee at the then-established Budapest office of Linklaters, and during my early years I was also seconded to the firm’s London office. My early professional years also included time at a CEE-based independent firm and DLA Piper’s Budapest office before returning to Linklaters. In 2008, as a result of Linklaters’ withdrawal from the CEE region, partners from the affected offices laid the foundation for a new firm, leading to the creation of Kinstellar in November 2008. I became a partner in 2009, and head of the firm-wide energy service line. I was appointed managing partner of the Budapest office in 2020 and became Kinstellar’s firm managing partner as of January 2024.

Continue reading “Q&A: Kristóf Ferenczi, firm managing partner, discusses the future of Kinstellar”

Sponsored thought leadership: China life sciences – Transaction insights and notable industry trends

Posted on |
Sponsored thought leadership: China life sciences – Transaction insights and notable industry trends

China’s life sciences and healthcare (LS&H) industry underwent an unprecedented transformation in 2023 consisting of numerous challenges and opportunities. Within this year, BD transactions primarily included out-licensing of ex-China rights, China commercialisation partnering, asset acquisition and regaining drug product rights, which reflected the courage of China’s LS&H market players to proactively seek changes and rebuild corporate strategies in a quickly shifting market landscape.

Fangda Partners’ life sciences team remained active in advising on LS&H corporate transactions in 2023 and recent key deal highlights included (a) Hengrui Pharma (600276.SH)’s out-licensing partnership with Aiolos Bio to exploit the innovative anti-TSLP mAb (SHR-1905) outside of Greater China; (b) Kanghua Biological (300841.SZ)’s grant of exclusive rights to HilleVax for exploitation of recombinant hexavalent VLP norovirus vaccine outside of Greater China; (c) CStone Pharma (2616.HK)’s sale of the Tibsovo® (Ivosidenib) business, asset and goodwill thereof in Greater China and Singapore to Les Laboratoires Servier; and (d) a number of commercialisation arrangements entered into by multinational pharmaceutical companies with leading CSOs. Continue reading “Sponsored thought leadership: China life sciences – Transaction insights and notable industry trends”

Sponsored Q&A: Fangda Partners

Posted on |
Sponsored Q&A: Fangda Partners

1. What are the current regulatory frameworks governing the life sciences industry in China, and how have they evolved in recent years?

Legislation wise, the Drug Administration Law and its implementation rules are pivotal to the pharmaceutical sector, overseeing the entire lifecycle of chemical and biological products. For medical devices (including in-vitro diagnostics), the Regulations for the Supervision and Administration of Medical Devices form a fundamental framework. Continue reading “Sponsored Q&A: Fangda Partners”

The Electronic Transactions and Data Protection Law in Lebanon: Empowering Lebanese companies in the digital age

Posted on |
The Electronic Transactions and Data Protection Law in Lebanon: Empowering Lebanese companies in the digital age

In an era marked by rapid advancements in technology and an ever-expanding digital landscape, the significance of robust legal frameworks governing electronic transactions and data protection cannot be overstated. For Lebanese companies, the enactment of the Lebanese Law No. 81 of 2018 related to electronic transactions and personal data (Law No. 81/2018 or ‘Law’) represents a pivotal moment in their journey towards adapting to the demands and opportunities of the digital age. This legislation not only addresses the critical need for legal clarity in electronic transactions but also establishes essential safeguards for data protection in an environment characterised by evolving cyber security threats and heightened concerns about privacy.

Lebanon, like many nations worldwide, has been experiencing a digital transformation that has reshaped the way businesses operate, communicate, and engage with their customers. E-commerce, online banking, and digital marketing have become integral components of the Lebanese business landscape, offering companies new avenues for growth and innovation. However, the absence of comprehensive electronic transactions regulations had left many enterprises navigating this digital terrain without clear guidelines, resulting in uncertainty and potential legal risks. Continue reading “The Electronic Transactions and Data Protection Law in Lebanon: Empowering Lebanese companies in the digital age”

International round-up: Global 100 firms expand in the Middle East and Asia

Posted on | and
International round-up: Global 100 firms expand in the Middle East and Asia

Ahead of our annual Global 100 report in our November/December issue, firms have made concerted efforts to consolidate and expand in the Middle East and Asia in recent months.

Bird & Bird has announced a new office in Shenzhen, to be led by the firm’s Greater China intellectual property practice co-head Hank Leung, a Legal 500 leading individual for IP in Hong Kong. The new office will work closely with lawyers from the firm’s international network, including its offices in Beijing, Shanghai, and Hong Kong. Continue reading “International round-up: Global 100 firms expand in the Middle East and Asia”

Ireland focus: No line on the horizon

Posted on |
Ireland focus: No line on the horizon

‘What’s happening with Kirkland would make a great Netflix documentary, although maybe a bit niche,’ quips one managing partner of the recent saga of the Chicago-bred powerhouse and Paul Weiss’ London office. ‘Let’s hope they’ve had cameras dotted around the office!’ The amused detachment with which the remark is delivered could be said to sum up the stance of Ireland’s law firm leaders in the round – often looking on at the dramas besetting other international markets from a rarefied position of relative immunity to the worst of the upheavals faced elsewhere in the world.

However, no market is an island, and many of the challenges faced by Ireland’s leading firms this time last year not only remain but have become more urgent. Managing partners are just as alive to reversals created by an ultra-competitive recruitment environment, not helped by a cost-of-living crisis that shows little sign of releasing its grip any time soon, while the ongoing war in Ukraine and related upward spiral of interest rates and inflation continue to make themselves felt. Continue reading “Ireland focus: No line on the horizon”

Sponsored briefing: A brief overview of Dutch alternatives for participation structures

Posted on |
Sponsored briefing: A brief overview of Dutch alternatives for participation structures

VanLoman partners Marc Oostenbroek and Gabriël van Gelder explore the advantages and disadvantages of structures for employee participation commonly used in the Netherlands

Participation structures are an often-used method to bind employees/managers to the company and to share the value increase realised. In the Netherlands generally four kinds of participation structures are used: stock options; stock appreciation rights (SARs); shares; and carried interest. Continue reading “Sponsored briefing: A brief overview of Dutch alternatives for participation structures”

Sponsored Q&A: Nicholas Blake-Knox – partner and head of Walkers’ asset management and investment funds group in Ireland

Posted on |
Sponsored Q&A: Nicholas Blake-Knox – partner and head of Walkers’ asset management and investment funds group in Ireland

Can you tell us a little bit about your career and how you ended up at Walkers?

When I graduated from University College Dublin in 2001 with a business and law degree I wasn’t entirely sure what I wanted to do. A friend in university had started working in a finance role within a fund administrator and he told me that if I joined and stayed for three months that he would get a €500 referral bonus. I joined. He got the referral bonus (which he didn’t share with me incidentally) and subsequently left to become a primary school teacher. Ironically, I have remained in the funds industry ever since. My legal career began a couple of years later with one of the leading domestic firms in Dublin, where I was earmarked for their investment funds group when I finished my traineeship. In 2011, I moved to London and joined the global asset management firm, PIMCO. I stayed in London with PIMCO for almost seven years before returning to Ireland in 2018 when I joined Walkers. During my time in London I completed an MBA at London Business School and briefly considered the idea of moving out of a legal role but ultimately stuck with a career in the legal profession. I feel that I have made the right choice and enjoy working in the funds industry in Ireland. Last year, I was elected to the Council of Irish Funds (the asset management and investment funds industry association here) and recently have been appointed to the role of vice chair of the association and consequently will assume the role of chair next year. Continue reading “Sponsored Q&A: Nicholas Blake-Knox – partner and head of Walkers’ asset management and investment funds group in Ireland”

Sponsored briefing: Challenges and strategies in a competitive market

Posted on |
Sponsored briefing: Challenges and strategies in a competitive market

Lisa Broderick of DAC Beachcroft examines the key problems and priorities for Irish clients, as well as the firm’s recent international growth and adaptations post-Covid

DACB Dublin is part of DAC Beachcroft LLP, an international law firm with over 2,800 professionals and a legal network advising across the United Kingdom, Europe, Asia-Pacific, Latin America and North America. Continue reading “Sponsored briefing: Challenges and strategies in a competitive market”